Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of ...

KRAZATI became the first KRAS inhibitor to get the regulatory nod for the treatment of KRAS G12C–mutant locally advanced or metastatic colorectal cancer. When it comes to biomarker-specific ...

KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition Session Date and Time: Friday, ...

At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...

Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright ... FDA-approved as second-line therapies for KRAS G12C-mutated non-small cell lung cancer (NSCLC ...

The researchers combined a newly identified KRAS G12C inhibitor, with a compound that blocks a protein called SHP2, which inhibits cancer cells and can also activate tumor immunity. These two ...

Also, Roche’s KRAS G12C inhibitor divarasab has shown a 62% ORR when combined with Erbitux in a phase 1 trial. The data readout for Cardiff’s CRDF-004 trial is imminent now. The trial is still ...

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from ...

REDWOOD CITY, CA, USA I3, 2024 I Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging ...

Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as ...

ALTA3263 demonstrates preclinical antitumor activity in the most common KRAS mutant cancers IND-enabling studies are ongoing to support clinical trial initiation in early 2025 Alterome Therapeutics ...